Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study.
Smith
Don E
DE
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.
Carr
Andrew
A
Law
Matthew
M
Martin
Allison
A
Hudson
Jeff
J
Hoy
Jennifer
J
Cooper
David A
DA
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018119:Stavudine / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome; D013936:Thymidine / Q000031:analogs & derivatives*; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D015215:Zidovudine; D018119:Stavudine; D013936:Thymidine